Overview

A Study to Evaluate the Efficacy and Safety of ZYIL1 Oral Capsules for the Treatment of Patients With Mild to Moderately Active Ulcerative Colitis Resistant or Intolerant to Oral Aminosalicylates

Status:
COMPLETED

Trial end date:
2024-11-28

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate efficacy and safety of ZYIL1 oral capsule twice a day for 12 weeks for treatment of mild to moderate active ulcerative colitis resistant or intolerant to oral aminosalicylates.

Phase:

PHASE2

Details

Lead Sponsor:

Zydus Lifesciences Limited

Treatments:

26S proteasome non-ATPase regulatory subunit 13
DMAC2L protein, human